Equity Research Health Information Services

Should You Buy OneMedNet Corporation Stock in 2026?

By CirclFi Research Team · · Updated · 1/13 models active

According to the CirclFi Deep Alpha Valuation Engine, OneMedNet Corporation (ONMD) scores 4.8/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $0.65, our multi-model valuation analyzes whether the market has already discounted these weaknesses.

The short answer: 0 of 1 CirclFi valuation models project upside for OneMedNet Corporation (ONMD) at $0.65 — the model consensus leans bearish, with a Quality Score of 4.8/10 and Value-Trap risk of 33/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 1 of 1 models suggest overvaluation — majority bearish
  • Quality Score: 4.8/10 — Weak — below-average fundamentals
  • Value Trap Risk: 33/100 — Low — manageable risk
  • Fair Value Range: $0.02 – $0.02 (0% spread)

Bullish Models

0 / 1

Bearish Models

1 / 1

Quality Score

4.8 /10

Weak — below-average fundamentals

Value Trap Risk

33 /100
Low

Low — manageable risk

Model Consensus

1 /13
Active Models

Avg. confidence: 52%

What Is the Investment Case for OneMedNet Corporation (ONMD) in 2026?

What Is the Bull Case vs the Bear Case for OneMedNet Corporation (ONMD)?

Bull case versus bear case for OneMedNet Corporation (ONMD) at $0.65, derived from 1 active CirclFi valuation models on 2026-09-15.
Bull case Bear case — $0.02 target (-96.4%)
No active model projects meaningful upside for ONMD at $0.65. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. According to the CirclFi Quality of Company (QOC) framework, OneMedNet Corporation's score of 4.8/10 signals fundamental weaknesses that could undermine the investment thesis.
According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $0.02 (-96.4%), suggesting that the market price embeds overly optimistic growth assumptions.

How Does ONMD Compare to Its Health Information Services Peers?

VSEE VSee Health, Inc.
4.8
BEAT HeartBeam, Inc.
4.7
WORX SCWorx Corp.
4.8
MSPR MSP Recovery, Inc.
4.7
LGMK LogicMark, Inc.
4.9
RVRC Revium Rx.
4.5
HSTM HealthStream, Inc.
8.7
TDOC Teladoc Health, Inc.
7.3

Valuation data pages: VSEE · BEAT · WORX · MSPR · LGMK · RVRC · HSTM · TDOC · HTFL · DOCS · HQY

See full Health Information Services rankings →

Which Other Stocks Score Like ONMD on Quality?

Closest companies to ONMD’s Quality of Company score of 4.8/10, across all industries.

Why Do CirclFi’s 1 Models Disagree on ONMD?

Spread

0%

Fair Value Range

$0.02 – $0.02

A tight 0% spread suggests meaningful convergence, strengthening conviction in the composite estimate.

Most Bullish

Dynamic NAV

$0.02 (-96.4%)

Most Bearish

Dynamic NAV

$0.02 (-96.4%)

What Are the Biggest Risks of Buying ONMD Stock?

Weak Fundamentals

QOC 4.8/10 signals below-average quality.

Bearish Consensus

1/1 models suggest overvaluation.

Macro/Sector Risk

Health Information Services headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View ONMD Data Page →

So Is OneMedNet Corporation (ONMD) Worth Buying in 2026?

Our valuation engine sends a clear cautionary signal on OneMedNet Corporation at $0.65. 1/1 models flag overvaluation, median fair value sits at $0.02 (-96.4%), and the risk-reward profile appears unfavorable. Quality at 4.8/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. OneMedNet Corporation's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About ONMD Stock?

Should I buy ONMD stock right now?

Based on CirclFi's multi-model analysis, 0 of 1 models see upside for ONMD at $0.65. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in OneMedNet Corporation?

Key risks include: a below-average Quality Score of 4.8/10, indicating fundamental weakness; limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Health Information Services companies. Always diversify and consult a financial advisor.

How does ONMD compare to its competitors?

Among Health Information Services peers, ONMD holds a Quality Score of 4.8/10. Comparable companies include VSEE (QOC 4.8), BEAT (QOC 4.7), WORX (QOC 4.8). The relative ranking helps investors identify whether ONMD offers better fundamental quality than alternatives in the same sector.

Is ONMD a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ONMD's Quality Score of 4.8/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.

What price should I buy ONMD at?

CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $0.02 to $0.02. At $0.65, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for ONMD.

View ONMD Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →